Policies & Disclaimers  |  Contact Us  |  Site Map  |  Important Safety Information   
Inhaled Ventavis® (iloprost) Inhalation Solution Breathe In the Power of Prostacyclin In Pulmonary Arterial Hypertension (PAH) NYHA Class III or IV
     Sure Steps Program
PAH Pathways - Actelion Services & Support
Download 20 mcg/mL Medication Order Form
Download the
Ventavis Patient
Enrollment Forms

Sure Steps Program

Ventavis® (iloprost) Inhalation Solution patients also have the choice to enroll in the Sure Steps™ program, a highly effective support program† staffed by registered nurses. Our Ventavis-trained nurse counselors are available to answer questions about pulmonary arterial hypertension (PAH), Ventavis therapy, I-neb AAD System cleaning and maintenance as well as the Sure Steps program. The Sure Steps program offers:

  • Telephone support with registered nurses who are specially trained in PAH and Ventavis. These friendly nurse counselors can answer your patient's questions regarding PAH or Ventavis and may guide them to more resources.
  • Information-packed newsletters and mailings about PAH and Ventavis that give your patients new insights and tips on a regular basis.
  • Online information, available 24 hours a day.
  • Your patients can enroll in Sure Steps by calling 1.866.682.SURE (7873).

† Data on file, Actelion Pharmaceuticals US, Inc [Harris Poll]

I-neb AAD System User Guide
The I-neb AAD System is a registered trademark of Philips Respironics.



* In the AIR pivotal trial, Ventavis delivered significant patient improvement in a composite endpoint consisting of ≥10% increase in 6MWD, improvement in NYHA functional class, and lack of deterioration or death (p=0.0033).

IMPORTANT SAFETY INFORMATION:
In clinical studies, common adverse reactions due to Ventavis included vasodilation (flushing), cough, headache, trismus, and insomnia. Serious adverse events reported at a rate of less than 3% included congestive heart failure, chest pain, supraventricular tachycardia, dyspnea, peripheral edema, and kidney failure. Vital signs should be monitored while initiating Ventavis. Ventavis should not be initiated in patients with systolic blood pressure less than 85 mmHg. Stop Ventavis immediately if signs of pulmonary edema occur; this may be a sign of pulmonary venous hypertension.

Please see full Prescribing Information

For more information about
Ventavis, please call
1-866-ACTELION (1-866-228-3546).

Policies & Disclaimers  |  Contact Us  |  Site Map  |  Important Safety Information

THIS SITE IS INTENDED FOR U.S. AUDIENCES ONLY.
SECOND WIND is a licensed trademark of Pulmonary Rehabilitation Associates.
©2010 Actelion Pharmaceuticals US, Inc. All rights reserved.

ACTELION